Biofortuna launches its new approach to custom IVD manufacture and development services

July 27, 2015 - PRLog -- Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market.

World-renowned for its lyophilisation services and molecular diagnostic products, Biofortuna has developed a new internal infrastructure, creating distinct products and services divisions and giving the company a strong focus for growth and efficiency. The breadth of the company’s portfolio of IVD manufacturing and development services has expanded to include manufacturing, dispensing, kitting, labelling, capping, as well as design and development of molecular diagnostic kits.

Biofortuna is an ISO 13485 certified company based in the UK, with state-of-the-art FDA registered facilities, including molecular biology laboratories. The company uniquely offers a strong scientific basis to its manufacturing services, giving customers a level of understanding and flexibility, in regulatory issues as well as development and manufacturing challenges, that few IVD contract manufacturers can boast.

Dr Simon Douglas, CEO of Biofortuna, said: “We pride ourselves on understanding our customers’ requirements and custom designing projects to meet their needs. Our recent expansion and restructuring builds on this successful approach, and we look forward to providing existing and future customers with a broad portfolio of services.”

For further information, visit booth #4565 at the AACC, contact services@biofortuna.com or visit www.biofortuna.com.

About Biofortuna

Biofortuna Ltd. is a venture capital backed IVD company based in the north west of the UK. Founded in 2008, it has two divisions: a custom manufacture and development division and a molecular diagnostic products division. The custom manufacture and development group is a leader in freeze drying and stabilisation of molecular diagnostic assays. It offers a contract IVD production and development service in its FDA and ISO 13485 approved facilities to companies wanting to deliver simple one-step protocols by converting liquid tests into freeze dried kits. It also manufactures liquid based kits and offers dispensing and kitting services. The molecular diagnostic products division has a range of stabilised PCR-based kits (SSPGo) for the transplantation and disease identification markets, with further molecular diagnostic products against other human genomic targets currently under development.